|
 "We are at the very beginning and want to achieve our goal. There
are a number of questions... You see that it is a complex
procedure," CEO Andreas Barner told journalists in a conference
call.
He confirmed Boehringer and Sanofi's goal to close the transaction
in the fourth quarter of 2016, subject to regulatory approvals.
Sanofi and Boehringer are in exclusive talks over a $20 billion swap
of the French pharmaceuticals company's animal health business for
the family-owned German group's consumer health operation.
Barner said there was "practically no overlap" in the animal health
and consumer healthcare businesses that are to be merged, which was
good for employment prospects of affected staff.
(Reporting by Ludwig Burger; Editing by Kirsti Knolle)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
